CTNM vs. ZYME, STOK, VALN, VERV, CRMD, SYRE, MLYS, CRON, PGEN, and PRAX
Should you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Zymeworks (ZYME), Stoke Therapeutics (STOK), Valneva (VALN), Verve Therapeutics (VERV), CorMedix (CRMD), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Cronos Group (CRON), Precigen (PGEN), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.
Contineum Therapeutics vs. Its Competitors
Zymeworks (NASDAQ:ZYME) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.
Contineum Therapeutics has a consensus target price of $22.75, indicating a potential upside of 126.37%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Contineum Therapeutics is more favorable than Zymeworks.
Contineum Therapeutics has a net margin of 0.00% compared to Zymeworks' net margin of -59.96%. Zymeworks' return on equity of -21.59% beat Contineum Therapeutics' return on equity.
Zymeworks has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.
Contineum Therapeutics has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Contineum Therapeutics had 2 more articles in the media than Zymeworks. MarketBeat recorded 2 mentions for Contineum Therapeutics and 0 mentions for Zymeworks. Contineum Therapeutics' average media sentiment score of 0.90 beat Zymeworks' score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the news media.
92.9% of Zymeworks shares are owned by institutional investors. 1.9% of Zymeworks shares are owned by insiders. Comparatively, 11.3% of Contineum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Contineum Therapeutics beats Zymeworks on 10 of the 16 factors compared between the two stocks.
Get Contineum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Contineum Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CTNM) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access